胰岛素样生长因子家族在肺癌中的研究进展  

Progress in the research of insulin-like growth factor family in lung cancer

作　　者：游良琨[1,2] 廖永德[1] 付圣灵[1] 具晟[1,2] 陈广[1,2] 邢昕[1,2] 

机构地区：[1]华中科技大学同济医学院同济医院普胸外科,武汉430030 [2]华中科技大学同济医学院第二临床学院,武汉430030

出　　处：《肿瘤》2010年第4期356-360,共5页Tumor

摘　　要：正常人体内的胰岛素样生长因子(insulin-likegrowthfactor,IGF)通过受体和结合蛋白的调节,在细胞的增殖、分化和凋亡中起重要作用。越来越多的研究发现,IGF家族参与包括肺癌在内的众多恶性肿瘤的发生和发展。近年来对肺癌细胞系、肺癌组织和肺癌患者循环血中IGF及其家族成员开展的大量基础和临床研究的结果显示,IGF家族可能在肺癌的转化和恶性进展中起重要作用,抑制其受体信号通路可能为肺癌的综合治疗提供新靶点。针对IGF受体的单克隆抗体研究目前已进入Ⅱ期临床试验阶段,并显示出潜在的临床应用前景。本文就IGF家族在肺癌领域的最新研究进展进行综述。Insulin-like growth factors（IGF）,regulated by their receptors and binding proteins,play a pivotal role in human cell proliferation,differentiation and apoptosis.Increasing evidence has revealed that IGF system is involved in the genesis and progress of various malignancies including lung cancer.Recent studies in regard to IGF axis expression in the lung cancer cell lines,pulmonary tissue samples and blood circulation of lung cancer patients have shown that the IGF axis may contribute to the transformation and progression of lung cancer.Several researches have shown that a number of drugs targeting the IGF receptor are being investigated in clinical trials and suggest a potential therapeutic efficacy.This article reviews the updates and progress in the research of IGF axis in lung cancer.

关 键 词：肺肿瘤 生长调节素类 受体 生长调节素 胰岛素样生长因子结合蛋白质类 

分 类 号：R734.2[医药卫生—肿瘤]